bioAffinity Technologies, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
SAN ANTONIO, May 12, 2026--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to the same period in 2025, based on preliminary unaudited data. The strong CyPath® Lung unit sales growth so far this year continues to exceed the Company’s internal projec
SAN ANTONIO, May 08, 2026--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026.
SAN ANTONIO, April 28, 2026--bioAffinity Technologies announces study with Brooke Army Medical Center to evaluate new diagnostic tests to improve treatment for asthma and COPD
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
SAN ANTONIO, April 14, 2026--Patient case study in which CyPath Lung spared a high-risk patient with a suspicious nodule and elevated risk from an invasive biopsy,
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis April 8,...
SAN ANTONIO, April 07, 2026--CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual lung cancer symposium.
SAN ANTONIO, April 01, 2026--bioAffinity Technologies’ CyPath Lung Sales Surged 146% Year-Over-Year in Q1 2026, gaining traction in the U.S. addressable market of $3.58 billion
SAN ANTONIO, March 25, 2026--bioAffinity Technologies will host a webinar on April 8 with leading pulmonologists who will share their clinical experience with CyPath Lung.
Nu Holdings Ltd. 21,063,342 14.91
Nu Holdings Ltd. 74,509,403 14.92
SAN ANTONIO, March 17, 2026--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in physician decision-making and patient outcome.
SAN ANTONIO, February 25, 2026--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
SAN ANTONIO, Texas, February 19, 2026--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan.
SAN ANTONIO, November 14, 2025--bioAffinity Technologies reports Q3 2025 financial results, achieves 86% increase in CyPath® Lung testing revenue.
SAN ANTONIO, November 05, 2025--bioAffinity Technologies announced the volume of CyPath® Lung tests processed in October increased by 111% over the 2025 monthly average.
SAN ANTONIO, October 28, 2025--Australian Patent Office accepts bioAffinity Technologies' patent application for its platform technology to assess lung health and predict disease.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 14.4K | $55.10K | 0.00% | New | 2026-03-31 |